Study supports link between injectable hormonal contraceptive and HIV risk
Wise, J.
Bmj 350: H112
2015
ISSN/ISBN: 1756-1833 PMID: 25575721 DOI: 10.1136/bmj.h112Document Number: 624943
Document emailed within 0-6 h
Related Documents
Smit, J.A.; Beksinska, M.E. 2013: Hormonal contraceptive continuation and switching in South Africa: implications for evaluating the association of injectable hormonal contraceptive use and HIV Journal of Acquired Immune Deficiency Syndromes 62(3): 363-365Smit, J.A.; Beksinska, M.E. 2013: Hormonal contraceptive continuation and switching in South Africa: implications for evaluating the association of injectable hormonal contraceptive use and HIV Journal of Acquired Immune Deficiency Syndromes 62(3): 363-365
Smit, J.A.; Beksinska, M.E. 2013: Hormonal contraceptive continuation and switching in South Africa: implications for evaluating the association of injectable hormonal contraceptive use and HIV Journal of Acquired Immune Deficiency Syndromes 62(3): 363-365
Konstantinus, I.N.; Balle, C.; Jaumdally, S.Z.; Galmieldien, H.; Pidwell, T.; Masson, L.; Tanko, R.F.; Happel, A.-U.; Sinkala, M.; Myer, L.; Bosinger, S.E.; Gill, K.; Bekker, L.-G.; Jaspan, H.B.; Passmore, J.-A.S. 2020: Impact of Hormonal Contraceptives on Cervical T-helper 17 Phenotype and Function in Adolescents: Results from a Randomized, Crossover Study Comparing Long-acting Injectable Norethisterone Oenanthate (NET-EN), Combined Oral Contraceptive Pills, and Combined Contraceptive Vaginal Rings Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 71(7): E76-E87
Taurand, S. 1989: Injectable hormonal progestational contraceptive agents Soins. Gynecologie Obstetrique Puericulture Pediatrie 1989(93): I-Ii
Beksinska, M.E.; Rees, V.H.; Nkonyane, T.; McIntyre, J.A. 1998: Compliance and use behaviour, an issue in injectable as well as oral contraceptive use? a study of injectable and oral contraceptive use in Johannesburg British Journal of Family Planning 24(1): 21-23
Beksinska, M.E.; Rees, V.H.; Nkonyane, T.; McIntyre, J.A. 1998: Compliance and use behaviour, an issue in injectable as well as oral contraceptive use? a study of injectable and oral contraceptive use in Johannesburg British Journal of Family Planning 24(1): 21-23
Grabowski, M.K.; Gray, R.H.; Makumbi, F.; Kagaayi, J.; Redd, A.D.; Kigozi, G.; Reynolds, S.J.; Nalugoda, F.; Lutalo, T.; Wawer, M.J.; Serwadda, D.; Quinn, T.C.; Tobian, A.A.R. 2015: Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda Lancet. Global Health 3(8): E478-E486
Mia, A.R.; Siddiqui, N.I.; Islam, M.N.; Khan, M.R.; Shampa, S.S.; Rukunuzzaman, M. 2005: Effects of prolonged use of injectable hormonal contraceptive on serum lipid profile Mymensingh Medical Journal: Mmj 14(1): 19-21
Kamischke, A.; Heuermann, T.; Krüger, K.; von Eckardstein, S.; Schellschmidt, I.; Rübig, A.; Nieschlag, E. 2002: An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations Journal of Clinical Endocrinology and Metabolism 87(2): 530-539
Murphy, K.; Irvin, S.C.; Herold, B.C. 2014: Research gaps in defining the biological link between HIV risk and hormonal contraception American Journal of Reproductive Immunology 72(2): 228-235
Andersen, L.; Friis, S.ør.; Hallas, J.; Ravn, P.; Kristensen, B.W.; Gaist, D. 2015: Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study British Journal of Clinical Pharmacology 79(4): 677-684
Beksinska, M.E.; Smit, J.A.; Ramkissoon, A. 2010: Progestogen-only injectable hormonal contraceptive use should be considered in analysis of studies addressing the loss of bone mineral density in HIV-positive women Journal of Acquired Immune Deficiency Syndromes 54(4): E5
Butler, A.R.; Smith, J.A.; Polis, C.B.; Gregson, S.; Stanton, D.; Hallett, T.B. 2013: Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk Aids 27(1): 105-113
Misro, M.M.; Chaki, S.P.; Kaushik, M.C.; Nandan, D. 2009: Trials for development of once-a-month injectable, hormonal male contraceptive using dienogest plus testosterone undecanoate: dose standardization, efficacy and reversibility studies in rats Contraception 79(6): 488-497
Ngcapu, S.; Masson, L.; Sibeko, S.; Werner, L.; McKinnon, L.R.; Mlisana, K.; Shey, M.; Samsunder, N.; Karim, S.A.; Karim, Q.A.; Passmore, J.-A.S. 2015: Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive Journal of Reproductive Immunology 110: 14-21
Baweja, R.; Bhattacharya, S.K.; Choudhury, S.D.; Krishna, U.; Manuel, M.; Phillips, F.S.; Datey, S.; Kumar, S.; Mehta, S.; Saxena, N.C. 1985: Indian Council of Medical Research. Task Force on Hormonal Contraception: Phase II randomized clinical trial with norethisterone oenanthate 50 mg alone and in combination with 5 mg or 2.5 mg of either estradiol valerate or cypionate as a monthly injectable contraceptive Contraception 32(4): 383-394
Chowdhury, T.A. 1985: A clinical study on injectable contraceptive Noristerat Bangladesh Medical Journal 14(2-3): 28-35
Chowdhury, T.A. 1985: A clinical study on injectable contraceptive Noristerat Bangladesh Medical Journal 14(2-3): 28-35
1988: A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. I: Contraceptive efficacy and side effects Contraception (Stoneham) 37(1): 1-20